secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001663577-26-000046
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.01, 5.03, 7.1, 8.1
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path issues Series S preferred to CEO entity, giving 51% voting control; cancels reverse split, plans trial restarts
--------------------------------------------------------------------------------

- Issued 51 Series S preferred shares (1% vote each) and 2M warrants to CEO-controlled SGA, granting 51% voting control.
- $10K accrued payables used as consideration for the preferred and warrants; no new capital raised.
- Filing to domesticate to Wyoming from Delaware; expected approval March 2026.
- In talks with creditors to restructure; plans to restart Phase 1/2 trials for AML, solid tumors, and obesity.
- Canceled previously approved 1-30 reverse split; created Strategic Advisory Board and reserved 1.5M incentive stock options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000166357726000046/0001663577-26-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000166357726000046/bpth_8k022426.htm
  HTML page:      https://secwatch.observer/filing/0001663577-26-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer